Researchers at Sanford Burnham Prebys, led by Ze’ev Ronai, Ph.D., have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. Published in Nature Cell Biology, these findings could lead to a new class of drugs to selectively treat melanoma, the most severe form of skin cancer.
Click here for original story, Inhibiting key metabolic enzyme shows promise against melanoma
Source: Phys.org